Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity
Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely l...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology and therapy Jg. 12; H. 5; S. 2241 - 2252 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Cheshire
Springer Healthcare
01.10.2023
Adis, Springer Healthcare |
| Schlagworte: | |
| ISSN: | 2193-8245, 2193-6528 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233–237,
https://doi.org/10.3928/15428877-20070501-09
, 2007, Shah et al. in Indian J Ophthalmol 55:75–76,
https://doi.org/10.4103/0301-4738.29505
, 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109–125,
https://doi.org/10.1080/08820530701420082
, 2007). |
|---|---|
| AbstractList | Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233–237,
https://doi.org/10.3928/15428877-20070501-09
, 2007, Shah et al. in Indian J Ophthalmol 55:75–76,
https://doi.org/10.4103/0301-4738.29505
, 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109–125,
https://doi.org/10.1080/08820530701420082
, 2007). Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233-237, https://doi.org/10.3928/15428877-20070501-09 , 2007, Shah et al. in Indian J Ophthalmol 55:75-76, https://doi.org/10.4103/0301-4738.29505 , 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109-125, https://doi.org/10.1080/08820530701420082 , 2007). Abstract Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233–237, https://doi.org/10.3928/15428877-20070501-09 , 2007, Shah et al. in Indian J Ophthalmol 55:75–76, https://doi.org/10.4103/0301-4738.29505 , 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109–125, https://doi.org/10.1080/08820530701420082 , 2007). Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233–237, 10.3928/15428877-20070501-09, 2007, Shah et al. in Indian J Ophthalmol 55:75–76, 10.4103/0301-4738.29505, 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109–125, 10.1080/08820530701420082, 2007). Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233-237, https://doi.org/10.3928/15428877-20070501-09 , 2007, Shah et al. in Indian J Ophthalmol 55:75-76, https://doi.org/10.4103/0301-4738.29505 , 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109-125, https://doi.org/10.1080/08820530701420082 , 2007).Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from the retina into the vitreous that lead to complex retinal detachments. Our understanding of ROP has evolved with the survival of extremely low-birthweight infants and includes not only overgrowth of blood vessels, but also insufficient developmental retinal vascular growth in early phases of the disease. Our current treatments of ROP have focused on methods to improve perinatal and prenatal care, reduce premature birth, and prevent early phases of ROP. Nonetheless, addressing vasoproliferation in treatment-warranted eyes remains the mainstay of management. Two main treatment strategies co-exist today: laser treatment, which has been the standard of care since the 1990s, and anti-VEGF injections, which have been used since early reports in 2007 (Travassos et al. in Ophthalmic Surg Lasers Imaging, 38:233-237, https://doi.org/10.3928/15428877-20070501-09 , 2007, Shah et al. in Indian J Ophthalmol 55:75-76, https://doi.org/10.4103/0301-4738.29505 , 2007, Quiroz-Mercado et al. in Semin Ophthalmol 22:109-125, https://doi.org/10.1080/08820530701420082 , 2007). |
| Author | Hartnett, M. Elizabeth Stahl, Andreas |
| Author_xml | – sequence: 1 givenname: M. Elizabeth surname: Hartnett fullname: Hartnett, M. Elizabeth email: me.hartnett@stanford.edu organization: Byers Eye Institute at Stanford University, Stanford University – sequence: 2 givenname: Andreas surname: Stahl fullname: Stahl, Andreas organization: Chair for Ophthalmology, University Medicine Greifswald, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37337024$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1v1DAQhiNUREvpH-CAcuQS8FdshwtaVf2SVqKCAgcO1iSe7HqVxIvtVNp_T9LdIsqhh5Et-32fV6OZ19nR4AfMsreUfKCEqI9REMp4QeYiSohCvchOGK14IUumjw53zUR5nJ3FuCFk0uuyEuJVdswV54owcZL9WkLEkN9jiGPMF0NyxY-Lq8tP-SK_hQDWrfr829q1KW99yO8CQupxSMVPCAGGhDb_iskNfgtpvct9m98G7CGNwaXdm-xlC13Es8N5mn2_vLg7vy6WX65uzhfLoik1SUWLFqXSlNcMZKVrVTWVRlaLmrOaCCs1qxSpmCK0qsGKuV1LRVNLKUtUkp9mN3uu9bAx2-B6CDvjwZmHBx9WBkJyTYdGMWlBttyiLkUNDJhqqSQELK8JozixPu9Z27Hu0TZTrwG6J9CnP4Nbm5W_N5QIwYigE-H9gRD87xFjMr2LDXYdDOjHaJhmqmJUyFn67t-wvymP45kEei9ogo8xYGsalyA5P2e7bgo18zKY_TIYMte8DEZNVvaf9ZH-rInvTXESDysMZuPHMEzDe871B21OxY4 |
| CitedBy_id | crossref_primary_10_3389_fmed_2025_1628325 crossref_primary_10_1001_jamaophthalmol_2025_2948 crossref_primary_10_1007_s12519_025_00919_1 crossref_primary_10_1159_000546935 crossref_primary_10_1038_s41598_024_66483_2 crossref_primary_10_3389_fped_2024_1382858 crossref_primary_10_1007_s10456_024_09917_9 crossref_primary_10_1136_bjo_2025_327597 crossref_primary_10_3390_ijms25158461 crossref_primary_10_1038_s41372_024_01997_1 crossref_primary_10_1039_D5BM00555H crossref_primary_10_1080_2576117X_2023_2287633 crossref_primary_10_48130_vns_0025_0004 |
| Cites_doi | 10.1016/j.ophtha.2016.06.054 10.1001/archopht.123.3.311 10.1016/s2352-4642(21)00195-4 10.1038/s41598-018-20278-4 10.1056/NEJM199311253292201 10.3928/15428877-20070501-09 10.5694/j.1326-5377.1951.tb109040.x 10.1001/archophthalmol.2010.72 10.1016/j.jaapos.2017.10.006 10.1056/NEJMra1208129 10.1016/s0140-6736(19)31344-3 10.1016/s2214-109x(18)30451-0 10.1038/pr.2015.181 10.1056/NEJMoa1007374 10.1136/bmjopen-2020-042384 10.1542/peds.2015-3218 10.1136/bjo.38.7.433 10.1111/aos.14852 10.1136/bjo.38.7.397 10.1016/j.ophtha.2014.07.050 10.1016/j.ophtha.2022.05.019 10.1016/j.jaapos.2022.11.020 10.1007/s10456-018-9618-5 10.1001/archophthalmol.2012.592 10.1542/peds.2018-3061 10.1016/j.ajo.2011.07.005 10.1167/iovs.14-15842 10.1167/tvst.9.8.43 10.1080/08820530701420082 10.1001/jamaophthalmol.2014.2772 10.1097/icu.0000000000000783 10.1542/peds.2018-3537 10.1167/iovs.13-11625 10.1016/j.ophtha.2021.05.031 10.4103/0301-4738.29505 10.1167/iovs.18-25525 10.1073/pnas.1010299108 10.1001/jama.2022.10564 10.1016/j.oret.2022.02.006 10.1007/s00280-007-0664-8 10.1016/j.ajo.2014.06.009 10.1097/iae.0000000000001493 10.1001/jamaophthalmol.2022.3788 10.1016/j.ophtha.2016.04.028 10.1001/jamapediatrics.2017.4838 10.1016/j.ajo.2022.10.020 10.1016/s0161-6420(97)30034-7 10.1016/j.ophtha.2022.06.042 10.1001/jamaophthalmol.2021.3192 10.1016/0002-9394(54)90845-4 10.1007/s00347-020-01250-y 10.1016/j.ophtha.2014.12.017 10.3928/23258160-20190401-05 10.1001/jamaophthalmol.2022.0030 10.1001/archopht.1988.01060130517027 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). |
| DBID | C6C AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1007/s40123-023-00744-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2193-6528 |
| EndPage | 2252 |
| ExternalDocumentID | oai_doaj_org_article_726da6f3de854ba2a27f1600ad3b021e PMC10442041 37337024 10_1007_s40123_023_00744_7 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Novartis Pharma funderid: http://dx.doi.org/10.13039/100008792 – fundername: Research to Prevent Blindness grantid: unrestricted funderid: http://dx.doi.org/10.13039/100001818 – fundername: National Eye Institute grantid: R01 EY015130; R01 EY017011 funderid: http://dx.doi.org/10.13039/100000053 – fundername: Pharmaceuticals Bayer funderid: http://dx.doi.org/10.13039/501100009109 – fundername: NEI NIH HHS grantid: R01 EY017011 – fundername: NEI NIH HHS grantid: R01 EY015130 – fundername: ; – fundername: ; grantid: unrestricted – fundername: ; grantid: R01 EY015130; R01 EY017011 |
| GroupedDBID | -A0 0R~ 2VQ 3V. 4.4 53G 7RV 7X7 8AO 8FI 8FJ AAKKN ABDBF ABEEZ ABUWG ACACY ACGFS ACMJI ACUHS ACULB ADBBV ADINQ ADRAZ AFGXO AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C24 C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ IAO IHR ITC KQ8 LGEZI LOTEE M48 M~E NADUK NAPCQ NXXTH O9- OK1 PIMPY PQQKQ PROAC RPM RSV SISQX SMD SOJ UKHRP ~JE AAYXX AFFHD CITATION PHGZM PHGZT PPXIY NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c580t-fede67813b2a698b79c98e2b4b32b04d682970927019bad40074d14cb6665e763 |
| IEDL.DBID | C24 |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001014951300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2193-8245 |
| IngestDate | Fri Oct 03 12:38:05 EDT 2025 Thu Aug 21 18:40:04 EDT 2025 Fri Sep 05 11:25:21 EDT 2025 Thu Apr 03 07:01:17 EDT 2025 Tue Nov 18 21:21:25 EST 2025 Sat Nov 29 02:17:09 EST 2025 Fri Feb 21 02:43:39 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Vitreoretinal surgery ROP Anti-VEGF Retinopathy of prematurity Laser |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c580t-fede67813b2a698b79c98e2b4b32b04d682970927019bad40074d14cb6665e763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1007/s40123-023-00744-7 |
| PMID | 37337024 |
| PQID | 2827921461 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_726da6f3de854ba2a27f1600ad3b021e pubmedcentral_primary_oai_pubmedcentral_nih_gov_10442041 proquest_miscellaneous_2827921461 pubmed_primary_37337024 crossref_citationtrail_10_1007_s40123_023_00744_7 crossref_primary_10_1007_s40123_023_00744_7 springer_journals_10_1007_s40123_023_00744_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-01 |
| PublicationDateYYYYMMDD | 2023-10-01 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cheshire |
| PublicationPlace_xml | – name: Cheshire – name: England |
| PublicationTitle | Ophthalmology and therapy |
| PublicationTitleAbbrev | Ophthalmol Ther |
| PublicationTitleAlternate | Ophthalmol Ther |
| PublicationYear | 2023 |
| Publisher | Springer Healthcare Adis, Springer Healthcare |
| Publisher_xml | – name: Springer Healthcare – name: Adis, Springer Healthcare |
| References | Marlow, Stahl, Lepore, Fielder, Reynolds, Zhu, Weisberger, Stiehl, Fleck (CR53) 2021; 5 Mintz-Hittner, Geloneck, Chuang (CR42) 2016; 123 Stahl, Bründer, Lagrèze, Molnár, Barth, Eter, Guthoff, Krohne, Pfeil (CR28) 2022; 100 Natarajan, Shankaran, Nolen, Sridhar, Kennedy, Hintz, Phelps, DeMauro, Carlo, Gantz (CR25) 2019 Avery, Castellarin, Steinle, Dhoot, Pieramici, See, Couvillion, Nasir, Rabena, Maia (CR40) 2017; 37 Ashton, Ward, Serpell (CR8) 1954; 38 Chawanpaiboon, Vogel, Moller, Lumbiganon, Petzold, Hogan, Landoulsi, Jampathong, Kongwattanakul, Laopaiboon (CR4) 2019; 7 Kennedy, Mintz-Hittner (CR26) 2018; 22 Simmons, Bretz, Wang, Kunz, Hajj, Kennedy, Yang, Suwanmanee, Kafri, Hartnett (CR18) 2018; 21 Morin, Luu, Superstein, Ospina, Lefebvre, Simard, Shah, Shah, Kelly (CR24) 2016 Kong, Bhatt, Demny, Coats, Li, Rahman, Smith, Steinkuller (CR41) 2015; 56 Quiroz-Mercado, Ustariz-González, Martinez-Castellanos, Covarrubias, Dominguez, Sanchez-Huerta (CR3) 2007; 22 Wang, Sawada, Sawada, Saishin, Liu, Ohji (CR50) 2014; 158 Fierson (CR34) 2018 (CR35) 2021; 118 Geloneck, Chuang, Clark, Hunt, Norman, Packwood, Tawansy, Mintz-Hittner (CR52) 2014; 132 Shah, Narendran, Tawansy, Raghuram, Narendran (CR2) 2007; 55 Becker, Wang, Simmons, Suwanmanee, Stoddard, Kafri, Hartnett (CR21) 2003; 2018 Barnett, Hubbard (CR46) 2021; 32 Hartnett, Toth (CR12) 2019; 50 Stahl, Krohne, Eter, Oberacher-Velten, Guthoff, Meltendorf, Ehrt, Aisenbrey, Roider, Gerding (CR30) 2018 Good, Hardy, Dobson, Palmer, Phelps, Tung, Redford (CR17) 2010; 128 Allen, Donohue, Dusman (CR9) 1993; 329 Travassos, Teixeira, Ferreira, Regadas, Travassos, Esperancinha, Prieto, Pires, van Velze, Valido (CR1) 2007; 38 Nitkin, Bamat, Lagatta, DeMauro, Lee, Patel, King, Slaughter, Campbell, Richardson (CR23) 2022; 140 Sato, Wada, Arahori, Kuno, Imoto, Iwahashi-Shima, Kusaka (CR32) 2012; 153 Lu, Bruno, Eppler, Novotny, Lum, Gaudreault (CR39) 2008; 62 CR14 Hwang, Hubbard, Hutchinson, Lambert (CR54) 2015; 122 Vander, Handa, McNamara, Trese, Spencer, Repka, Rubsamen, Li, Morse, Tasman (CR16) 1997; 104 Chang, Josan, Purohit, Patel, Xue (CR38) 2022; 129 Kong, Ming, Mi (CR51) 2021; 11 Ashton, Cook (CR5) 1954; 38 Hartnett (CR19) 2019; 60 Good (CR22) 2016; 123 Hellgren, Löfqvist, Hård, Hansen-Pupp, Gram, Ley, Smith, Hellström (CR48) 2016; 79 Fidler, Fleck, Stahl, Marlow, Chastain, Li, Lepore, Reynolds, Chiang, Fielder (CR49) 2020; 9 Campbell (CR7) 1951; 2 McCloskey, Wang, Jiang, Smith, Strange, Hartnett (CR20) 2013; 54 Hartnett (CR10) 2015; 122 Cool, DeFalco, Capel (CR45) 2011; 108 Hu, Blair, Shapiro, Lichtenstein, Galasso, Kapur (CR33) 2012; 130 Stahl, Lepore, Fielder, Fleck, Reynolds, Chiang, Li, Liew, Maier, Zhu (CR55) 2019; 394 Hartnett, Penn (CR11) 2012; 367 Palmer, Hardy, Dobson, Phelps, Quinn, Summers, Krom, Tung (CR15) 2005; 123 Patz (CR6) 1954; 38 Chiang, Quinn, Fielder, Ostmo, Paul Chan, Berrocal, Binenbaum, Blair, Peter Campbell, Capone (CR13) 2021; 128 Chiang, Chen, Kang, Chen, Wang, Liu, Chen, Hwang, Lai, Wu (CR29) 2023; 247 Stahl, Sukgen, Wu, Lepore, Nakanishi, Mazela, Moshfeghi, Vitti, Athanikar, Chu (CR31) 2022; 328 Hartnett, Wallace, Dean, Li, Boente, Dosunmu, Freedman, Golden, Kong, Prakalapakorn (CR47) 2022; 140 Wallace, Hercinovic, Freedman, Crouch, Bhatt, Hartnett, Yang, Rogers, Hutchinson, Good (CR27) 2023; 27 Kraker, Wallace, Beck, Saunders, Lorenzi, Melia, Li (CR37) 2021; 139 Mintz-Hittner, Kennedy, Chuang (CR36) 2011; 364 Freedman, Hercinovic, Wallace, Kraker, Li, Bhatt, Boente, Crouch, Hubbard, Rogers (CR43) 2022; 129 Fleck, Reynolds, Zhu, Lepore, Marlow, Stahl, Li, Weisberger, Fielder (CR44) 2022; 6 M McCloskey (744_CR20) 2013; 54 X Wang (744_CR50) 2014; 158 WV Good (744_CR22) 2016; 123 CR Nitkin (744_CR23) 2022; 140 JF Lu (744_CR39) 2008; 62 A Stahl (744_CR28) 2022; 100 A Travassos (744_CR1) 2007; 38 MF Chiang (744_CR13) 2021; 128 HA Mintz-Hittner (744_CR42) 2016; 123 A Stahl (744_CR31) 2022; 328 RT Kraker (744_CR37) 2021; 139 L Kong (744_CR41) 2015; 56 MB Allen (744_CR9) 1993; 329 J Hu (744_CR33) 2012; 130 G Natarajan (744_CR25) 2019 DK Wallace (744_CR27) 2023; 27 744_CR14 HA Mintz-Hittner (744_CR36) 2011; 364 WV Good (744_CR17) 2010; 128 ME Hartnett (744_CR11) 2012; 367 H Quiroz-Mercado (744_CR3) 2007; 22 RL Avery (744_CR40) 2017; 37 N Marlow (744_CR53) 2021; 5 EA Palmer (744_CR15) 2005; 123 MC Chiang (744_CR29) 2023; 247 E Chang (744_CR38) 2022; 129 S Becker (744_CR21) 2003; 2018 PK Shah (744_CR2) 2007; 55 KA Kennedy (744_CR26) 2018; 22 N Ashton (744_CR5) 1954; 38 ME Hartnett (744_CR12) 2019; 50 A Stahl (744_CR30) 2018 BW Fleck (744_CR44) 2022; 6 S Chawanpaiboon (744_CR4) 2019; 7 WM Fierson (744_CR34) 2018 MM Geloneck (744_CR52) 2014; 132 CK Hwang (744_CR54) 2015; 122 T Sato (744_CR32) 2012; 153 SF Freedman (744_CR43) 2022; 129 JM Barnett (744_CR46) 2021; 32 K Campbell (744_CR7) 1951; 2 ME Hartnett (744_CR19) 2019; 60 A Patz (744_CR6) 1954; 38 J Morin (744_CR24) 2016 ME Hartnett (744_CR10) 2015; 122 N Ashton (744_CR8) 1954; 38 JF Vander (744_CR16) 1997; 104 Q Kong (744_CR51) 2021; 11 A Stahl (744_CR55) 2019; 394 M Fidler (744_CR49) 2020; 9 AB Simmons (744_CR18) 2018; 21 German Society of, O.; German Retina Society e.,V.; Professional Association of German, O (744_CR35) 2021; 118 J Cool (744_CR45) 2011; 108 ME Hartnett (744_CR47) 2022; 140 G Hellgren (744_CR48) 2016; 79 |
| References_xml | – volume: 123 start-page: 1843 year: 2016 end-page: 1844 ident: CR22 article-title: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system publication-title: Ophthalmology doi: 10.1016/j.ophtha.2016.06.054 – volume: 123 start-page: 311 year: 2005 end-page: 318 ident: CR15 article-title: 15-Year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity publication-title: Arch Ophthalmol doi: 10.1001/archopht.123.3.311 – volume: 5 start-page: 698 year: 2021 end-page: 707 ident: CR53 article-title: 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial publication-title: Lancet Child Adolesc Health doi: 10.1016/s2352-4642(21)00195-4 – volume: 2018 start-page: 8 year: 2003 ident: CR21 article-title: Targeted knockdown of overexpressed VEGFA or VEGF164 in Muller cells maintains retinal function by triggering different signaling mechanisms publication-title: Sci Rep doi: 10.1038/s41598-018-20278-4 – volume: 329 start-page: 1597 year: 1993 end-page: 1601 ident: CR9 article-title: The limit of viability—neonatal outcome of infants born at 22 to 25 weeks' gestation publication-title: N Engl J Med doi: 10.1056/NEJM199311253292201 – volume: 38 start-page: 233 year: 2007 end-page: 237 ident: CR1 article-title: Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity publication-title: Ophthalmic Surg Lasers Imaging doi: 10.3928/15428877-20070501-09 – volume: 2 start-page: 48 year: 1951 ident: CR7 article-title: Intensive oxygen therapy as a possible cause of retrolental fibroplasia. A clinical approach publication-title: Med J Australia doi: 10.5694/j.1326-5377.1951.tb109040.x – volume: 128 start-page: 663 year: 2010 end-page: 671 ident: CR17 article-title: Final visual acuity results in the early treatment for retinopathy of prematurity study publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2010.72 – volume: 22 start-page: 61 year: 2018 end-page: 65.e61 ident: CR26 article-title: Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity publication-title: J AAPOS doi: 10.1016/j.jaapos.2017.10.006 – volume: 367 start-page: 2515 year: 2012 end-page: 2526 ident: CR11 article-title: Mechanisms and management of retinopathy of prematurity publication-title: N Engl J Med doi: 10.1056/NEJMra1208129 – volume: 394 start-page: 1551 year: 2019 end-page: 1559 ident: CR55 article-title: Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial publication-title: Lancet (London, England) doi: 10.1016/s0140-6736(19)31344-3 – volume: 7 start-page: e37 year: 2019 end-page: e46 ident: CR4 article-title: Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis publication-title: Lancet Glob Health doi: 10.1016/s2214-109x(18)30451-0 – volume: 79 start-page: 70 year: 2016 end-page: 75 ident: CR48 article-title: Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity publication-title: Pediatr Res doi: 10.1038/pr.2015.181 – volume: 364 start-page: 603 year: 2011 end-page: 615 ident: CR36 article-title: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity publication-title: N Engl J Med doi: 10.1056/NEJMoa1007374 – volume: 11 year: 2021 ident: CR51 article-title: Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis publication-title: BMJ Open doi: 10.1136/bmjopen-2020-042384 – year: 2016 ident: CR24 article-title: Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity publication-title: Pediatrics doi: 10.1542/peds.2015-3218 – volume: 38 start-page: 433 year: 1954 end-page: 440 ident: CR5 article-title: Direct observation of the effect of oxygen on developing vessels: preliminary report publication-title: Br J Ophthalmol doi: 10.1136/bjo.38.7.433 – volume: 100 start-page: e91 year: 2022 end-page: e99 ident: CR28 article-title: Ranibizumab in retinopathy of prematurity—one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study publication-title: Acta Ophthalmol doi: 10.1111/aos.14852 – volume: 38 start-page: 397 year: 1954 end-page: 432 ident: CR8 article-title: Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia publication-title: Br J Ophthalmol doi: 10.1136/bjo.38.7.397 – volume: 122 start-page: 200 year: 2015 end-page: 210 ident: CR10 article-title: Pathophysiology and mechanisms of severe retinopathy of prematurity publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.07.050 – volume: 129 start-page: 1120 year: 2022 end-page: 1128 ident: CR43 article-title: Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes publication-title: Ophthalmology doi: 10.1016/j.ophtha.2022.05.019 – volume: 27 start-page: e11 issue: 10 year: 2023 end-page: 10.e18 ident: CR27 article-title: Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity publication-title: J AAPOS doi: 10.1016/j.jaapos.2022.11.020 – volume: 21 start-page: 751 year: 2018 end-page: 764 ident: CR18 article-title: Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy publication-title: Angiogenesis doi: 10.1007/s10456-018-9618-5 – volume: 130 start-page: 1000 year: 2012 end-page: 1006 ident: CR33 article-title: Reactivation of retinopathy of prematurity after bevacizumab injection publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2012.592 – year: 2018 ident: CR34 article-title: Screening examination of premature infants for retinopathy of prematurity publication-title: Pediatrics doi: 10.1542/peds.2018-3061 – volume: 153 start-page: 327 year: 2012 end-page: 333e321 ident: CR32 article-title: Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2011.07.005 – volume: 56 start-page: 956 year: 2015 end-page: 961 ident: CR41 article-title: Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.14-15842 – volume: 9 start-page: 43 year: 2020 ident: CR49 article-title: Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial publication-title: Transl Vis Sci Technol doi: 10.1167/tvst.9.8.43 – volume: 22 start-page: 109 year: 2007 end-page: 125 ident: CR3 article-title: Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story publication-title: Semin Ophthalmol doi: 10.1080/08820530701420082 – volume: 132 start-page: 1327 year: 2014 end-page: 1333 ident: CR52 article-title: Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2014.2772 – ident: CR14 – volume: 32 start-page: 475 year: 2021 end-page: 481 ident: CR46 article-title: Complications of retinopathy of prematurity treatment publication-title: Curr Opin Ophthalmol doi: 10.1097/icu.0000000000000783 – year: 2019 ident: CR25 article-title: Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment publication-title: Pediatrics doi: 10.1542/peds.2018-3537 – volume: 54 start-page: 2020 year: 2013 end-page: 2026 ident: CR20 article-title: Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11625 – volume: 128 start-page: e51 year: 2021 end-page: e68 ident: CR13 article-title: International classification of retinopathy of prematurity, third edition publication-title: Ophthalmology doi: 10.1016/j.ophtha.2021.05.031 – volume: 55 start-page: 75 year: 2007 end-page: 76 ident: CR2 article-title: Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity publication-title: Indian J Ophthalmol doi: 10.4103/0301-4738.29505 – volume: 60 start-page: 1286 year: 2019 end-page: 1297 ident: CR19 article-title: Discovering mechanisms in the changing and diverse pathology of retinopathy of prematurity: the Weisenfeld award lecture publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.18-25525 – volume: 108 start-page: 167 year: 2011 end-page: 172 ident: CR45 article-title: Vascular-mesenchymal cross-talk through Vegf and Pdgf drives organ patterning publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1010299108 – volume: 328 start-page: 348 year: 2022 end-page: 359 ident: CR31 article-title: Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2022.10564 – volume: 6 start-page: 628 year: 2022 end-page: 637 ident: CR44 article-title: Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2022.02.006 – volume: 62 start-page: 779 year: 2008 end-page: 786 ident: CR39 article-title: Clinical pharmacokinetics of bevacizumab in patients with solid tumors publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-007-0664-8 – volume: 158 start-page: 738 year: 2014 end-page: 744.e731 ident: CR50 article-title: Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2014.06.009 – volume: 37 start-page: 1847 year: 2017 end-page: 1858 ident: CR40 article-title: Systemic pharmokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab publication-title: Retina (Philadelphia, Pa.) doi: 10.1097/iae.0000000000001493 – volume: 140 start-page: 1085 year: 2022 end-page: 1094 ident: CR23 article-title: Pulmonary hypertension in preterm infants treated with laser vs anti-vascular endothelial growth factor therapy for retinopathy of prematurity publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2022.3788 – volume: 123 start-page: 1845 year: 2016 end-page: 1855 ident: CR42 article-title: Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy publication-title: Ophthalmology doi: 10.1016/j.ophtha.2016.04.028 – year: 2018 ident: CR30 article-title: Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2017.4838 – volume: 247 start-page: 170 year: 2023 end-page: 180 ident: CR29 article-title: Neurodevelopmental outcomes for retinopathy of prematurity: a Taiwan premature infant follow-up network database study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2022.10.020 – volume: 104 start-page: 1731 year: 1997 end-page: 1735 ident: CR16 article-title: Early treatment of posterior retinopathy of prematurity: a controlled trial publication-title: Ophthalmology doi: 10.1016/s0161-6420(97)30034-7 – volume: 129 start-page: 1389 year: 2022 end-page: 1401 ident: CR38 article-title: A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity publication-title: Ophthalmology doi: 10.1016/j.ophtha.2022.06.042 – volume: 139 start-page: 1143 year: 2021 end-page: 1144 ident: CR37 article-title: Choice of dose level for a randomized clinical trial of low-dose bevacizumab vs laser for type 1 retinopathy of prematurity publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2021.3192 – volume: 38 start-page: 291 year: 1954 end-page: 308 ident: CR6 article-title: Oxygen studies in retrolental fibroplasia publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(54)90845-4 – volume: 118 start-page: 68 year: 2021 end-page: 77 ident: CR35 article-title: Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity publication-title: Der Ophthalmol doi: 10.1007/s00347-020-01250-y – volume: 122 start-page: 1008 year: 2015 end-page: 1015 ident: CR54 article-title: Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.12.017 – volume: 50 start-page: 228 year: 2019 end-page: 234 ident: CR12 article-title: Experimental evidence behind clinical trial outcomes in retinopathy of prematurity publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20190401-05 – volume: 140 start-page: 337 year: 2022 end-page: 344 ident: CR47 article-title: Plasma levels of bevacizumab and vascular endothelial growth factor after low-dose bevacizumab treatment for retinopathy of prematurity in infants publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2022.0030 – volume: 38 start-page: 291 year: 1954 ident: 744_CR6 publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(54)90845-4 – volume: 2018 start-page: 8 year: 2003 ident: 744_CR21 publication-title: Sci Rep doi: 10.1038/s41598-018-20278-4 – volume: 329 start-page: 1597 year: 1993 ident: 744_CR9 publication-title: N Engl J Med doi: 10.1056/NEJM199311253292201 – volume: 140 start-page: 337 year: 2022 ident: 744_CR47 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2022.0030 – volume: 56 start-page: 956 year: 2015 ident: 744_CR41 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.14-15842 – volume: 328 start-page: 348 year: 2022 ident: 744_CR31 publication-title: JAMA doi: 10.1001/jama.2022.10564 – volume: 2 start-page: 48 year: 1951 ident: 744_CR7 publication-title: Med J Australia doi: 10.5694/j.1326-5377.1951.tb109040.x – volume: 394 start-page: 1551 year: 2019 ident: 744_CR55 publication-title: Lancet (London, England) doi: 10.1016/s0140-6736(19)31344-3 – volume: 139 start-page: 1143 year: 2021 ident: 744_CR37 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2021.3192 – volume: 247 start-page: 170 year: 2023 ident: 744_CR29 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2022.10.020 – volume: 129 start-page: 1120 year: 2022 ident: 744_CR43 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2022.05.019 – volume: 122 start-page: 200 year: 2015 ident: 744_CR10 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.07.050 – volume: 37 start-page: 1847 year: 2017 ident: 744_CR40 publication-title: Retina (Philadelphia, Pa.) doi: 10.1097/iae.0000000000001493 – volume: 128 start-page: 663 year: 2010 ident: 744_CR17 publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2010.72 – volume: 130 start-page: 1000 year: 2012 ident: 744_CR33 publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2012.592 – volume: 108 start-page: 167 year: 2011 ident: 744_CR45 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1010299108 – volume: 11 year: 2021 ident: 744_CR51 publication-title: BMJ Open doi: 10.1136/bmjopen-2020-042384 – volume: 5 start-page: 698 year: 2021 ident: 744_CR53 publication-title: Lancet Child Adolesc Health doi: 10.1016/s2352-4642(21)00195-4 – volume: 55 start-page: 75 year: 2007 ident: 744_CR2 publication-title: Indian J Ophthalmol doi: 10.4103/0301-4738.29505 – volume: 7 start-page: e37 year: 2019 ident: 744_CR4 publication-title: Lancet Glob Health doi: 10.1016/s2214-109x(18)30451-0 – volume: 128 start-page: e51 year: 2021 ident: 744_CR13 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2021.05.031 – volume: 104 start-page: 1731 year: 1997 ident: 744_CR16 publication-title: Ophthalmology doi: 10.1016/s0161-6420(97)30034-7 – year: 2018 ident: 744_CR30 publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2017.4838 – volume: 140 start-page: 1085 year: 2022 ident: 744_CR23 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2022.3788 – volume: 50 start-page: 228 year: 2019 ident: 744_CR12 publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20190401-05 – volume: 364 start-page: 603 year: 2011 ident: 744_CR36 publication-title: N Engl J Med doi: 10.1056/NEJMoa1007374 – volume: 367 start-page: 2515 year: 2012 ident: 744_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMra1208129 – volume: 123 start-page: 311 year: 2005 ident: 744_CR15 publication-title: Arch Ophthalmol doi: 10.1001/archopht.123.3.311 – volume: 38 start-page: 233 year: 2007 ident: 744_CR1 publication-title: Ophthalmic Surg Lasers Imaging doi: 10.3928/15428877-20070501-09 – volume: 32 start-page: 475 year: 2021 ident: 744_CR46 publication-title: Curr Opin Ophthalmol doi: 10.1097/icu.0000000000000783 – volume: 38 start-page: 397 year: 1954 ident: 744_CR8 publication-title: Br J Ophthalmol doi: 10.1136/bjo.38.7.397 – volume: 22 start-page: 109 year: 2007 ident: 744_CR3 publication-title: Semin Ophthalmol doi: 10.1080/08820530701420082 – year: 2018 ident: 744_CR34 publication-title: Pediatrics doi: 10.1542/peds.2018-3061 – volume: 62 start-page: 779 year: 2008 ident: 744_CR39 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-007-0664-8 – volume: 123 start-page: 1843 year: 2016 ident: 744_CR22 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2016.06.054 – volume: 129 start-page: 1389 year: 2022 ident: 744_CR38 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2022.06.042 – volume: 38 start-page: 433 year: 1954 ident: 744_CR5 publication-title: Br J Ophthalmol doi: 10.1136/bjo.38.7.433 – volume: 54 start-page: 2020 year: 2013 ident: 744_CR20 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11625 – year: 2016 ident: 744_CR24 publication-title: Pediatrics doi: 10.1542/peds.2015-3218 – volume: 132 start-page: 1327 year: 2014 ident: 744_CR52 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2014.2772 – year: 2019 ident: 744_CR25 publication-title: Pediatrics doi: 10.1542/peds.2018-3537 – volume: 22 start-page: 61 year: 2018 ident: 744_CR26 publication-title: J AAPOS doi: 10.1016/j.jaapos.2017.10.006 – volume: 158 start-page: 738 year: 2014 ident: 744_CR50 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2014.06.009 – volume: 6 start-page: 628 year: 2022 ident: 744_CR44 publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2022.02.006 – volume: 21 start-page: 751 year: 2018 ident: 744_CR18 publication-title: Angiogenesis doi: 10.1007/s10456-018-9618-5 – volume: 118 start-page: 68 year: 2021 ident: 744_CR35 publication-title: Der Ophthalmol doi: 10.1007/s00347-020-01250-y – volume: 79 start-page: 70 year: 2016 ident: 744_CR48 publication-title: Pediatr Res doi: 10.1038/pr.2015.181 – volume: 153 start-page: 327 year: 2012 ident: 744_CR32 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2011.07.005 – ident: 744_CR14 doi: 10.1001/archopht.1988.01060130517027 – volume: 122 start-page: 1008 year: 2015 ident: 744_CR54 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.12.017 – volume: 123 start-page: 1845 year: 2016 ident: 744_CR42 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2016.04.028 – volume: 9 start-page: 43 year: 2020 ident: 744_CR49 publication-title: Transl Vis Sci Technol doi: 10.1167/tvst.9.8.43 – volume: 60 start-page: 1286 year: 2019 ident: 744_CR19 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.18-25525 – volume: 100 start-page: e91 year: 2022 ident: 744_CR28 publication-title: Acta Ophthalmol doi: 10.1111/aos.14852 – volume: 27 start-page: e11 issue: 10 year: 2023 ident: 744_CR27 publication-title: J AAPOS doi: 10.1016/j.jaapos.2022.11.020 |
| SSID | ssj0001285944 |
| Score | 2.349824 |
| SecondaryResourceType | review_article |
| Snippet | Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood vessels from... Abstract Retinopathy of prematurity (ROP), a leading cause of childhood blindness, has historically been associated with blindness from overgrowth of blood... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2241 |
| SubjectTerms | Anti-VEGF Internal Medicine Laser Medicine Medicine & Public Health Ophthalmology Retinopathy of prematurity Review ROP Vitreoretinal surgery |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQhRAXRPkMFGQkbmCROE5sc9uiLhygWkGBShwsO7ZpJMiibLYS_54ZJ7vqAioXDrkkzoc9Y89zPH6PkKfW61AUHpAb5w0TvCmYs1GxwJFz0mlbxZjEJuTxsTo91YsLUl-YEzbSA48N90Ly2ts6lj6oSjjLLZexgChtfekgPgUcfQH1XJhMjX9XVKWTkiv0yJIpLqppx0zaNycQSbAcDwihgsmdqJTI-_-GOP9MnPxt9TQFpflNcmNCk3Q21mKfXAndLXLt3bRefpt8eQtBqqeYerFe0Vk3tOzT0ev5SzqjC9tb3379Tj-ctXGggF3pySbpnH22fY9N7ul73BK9RN3in3QZ6aJHjtekeHeHfJwfnbx6wyY5BdZUKh9YDD5AaCpKx22tlZO60SpwJ1zJXS58jbtsc82RoN1Zj4LpwheicTDDqQKMQ3fJXrfswn1CG1FbIQKgD8AvOirLtYuVh8jGXbTCZ6TYNKdpJq5xlLz4ZrYsyckEJscDTWBkRp5t7_kxMm1cWvoQrbQtiSzZ6QT4jpl8x_zLdzLyZGNjA70Kl0psF5brlYGJqNRJ8zwj90abb19VyrKUAG0yona8Yedbdq907Vli7oa5r-C5gIc-3ziOmcaM1SWVffA_KvuQXOfo8SkR8YDsDf06PCJXm_OhXfWPU_f5Bcz-GUw priority: 102 providerName: Directory of Open Access Journals |
| Title | Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity |
| URI | https://link.springer.com/article/10.1007/s40123-023-00744-7 https://www.ncbi.nlm.nih.gov/pubmed/37337024 https://www.proquest.com/docview/2827921461 https://pubmed.ncbi.nlm.nih.gov/PMC10442041 https://doaj.org/article/726da6f3de854ba2a27f1600ad3b021e |
| Volume | 12 |
| WOSCitedRecordID | wos001014951300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2193-6528 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001285944 issn: 2193-8245 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAVX databaseName: SpringerOpen customDbUrl: eissn: 2193-6528 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001285944 issn: 2193-8245 databaseCode: C24 dateStart: 20121201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVoQYhLy1dpKKyMxA0sJY4T29yWqgsHqFZQYCUOkR3bbSRIqiRbiX-Px5tEWqgqwSGXxHFie-x59sy8QeilMtImifHIjdKSMFomRCsniKXAOamlypwLySb46alYreRyCArrRm_30SQZVuop2I2B-icxXF7vMcJ30O0sERLk-niIcdicrIhMhiyufjamRFCWDdEy11ezpZECcf91aPNvp8k_LKdBIS32_68p99HeAEDxfCMxD9AtWz9Edz8OJvZH6PsHr9daDN4a6w7P674iX0_eLd7gOV6qVpnq_Cf-fFG5Hnu4i89GP3XyTbUtjJLBnyCKuoFUx79w4_CyBVrYkCTvMfqyODk7fk-GDAykzETcE2eN9dosSTVVuRSay1IKSzXTKdUxMzkE5saSAqe7VgZyrDOTsFL7TVFm_dJ1gHbrpraHCJcsV4xZD1g85JFOKCq1y4xXhlQ7xUyEknEUinKgJ4csGT-KiVg59FoRwwW9VvAIvZreudyQc9xY-i0M7lQSiLXDjaY9L4Z5WnCaG5W71FiRMa2ootwlHhQqk2oPh2yEXoyiUfiJCNYVVdtm3RV-78plSJMeoScbUZk-lfI05R4NRUhsCdHWv2w_qauLQPbtt8uMxsxX-nqUpWJYZrobGvv034ofoXsUxDF4KT5Du327ts_RnfKqr7p2hnb4SszCLJuFQ4vfmvoeQA |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dj9QgECd6GvXF74_6iYlvStJS2oJv6-XWM-5tNrrqJT4QKHDXRFvTdk3872XYtsnq5RJ94KWltMDA_OjM_AahF8oImyTGIzdKS8JomRCtHCeWAuekFipzLiSbKJZLfnwsVkNQWDd6u48mybBTT8FuDNQ_iaF4vcdIcRFdAuoVkOv9IcZh-2eFZyJkcfWrMSWcsmyIljm7mR2NFIj7z0KbfztN_mE5DQppfuP_unITXR8AKJ5tJeYWumDr2-jK0WBiv4O-LrxeazF4a2w6PKv7inw-eDt_jWd4pVplqpPv-ONp5Xrs4S5ej37q5ItqW5glgz9AFHUDqY5_4cbhVQu0sCFJ3l30aX6w3j8kQwYGUmY87omzxnptlqSaqlxwXYhScEs10ynVMTM5BObGggKnu1YGcqwzk7BS-0NRZv3WdQ_t1U1tHyBcslwxZj1g8ZBHOK6o0C4zXhlS7RQzEUrGWZDlQE8OWTK-yYlYOYyajKHAqMkiQi-nZ35syTnOrf0GJneqCcTa4ULTnshhncqC5kblLjWWZ0wrqmjhEg8KlUm1h0M2Qs9H0ZB-IYJ1RdW22XTSn10LEdKkR-j-VlSmV6VFmhYeDUWI7wjRzrfs3qmr00D27Y_LjMbMN_pqlCU5bDPdOZ19-G_Vn6Grh-ujhVy8W75_hK5REM3gsfgY7fXtxj5Bl8uffdW1T8Na-w2bOx9I |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagoIoL70d4GokbWE0cJ7G5LaULiLJaQYFKPVh2bLeRIKmyWST-PR7nIRaqSoiDL4njxPbY8zkz8w1Cz5QRNkmMR26UloTRMiFaOU4sBc5JLVTmXEg2USwW_PBQLH-L4g_e7qNJso9pAJamuts5NW5nCnxjAAVIDMXrQEaKi-gSWKTg-LU7xDv0f1l4JkJGV78yU8Ipy4bImbOb2dBOgcT_LOT5twPlH1bUoJzm1_6_W9fR1QGY4lkvSTfQBVvfRNsfBtP7LXS07_Vdi8GLY73Cs7qryJe9N_OXeIaXqlWmOv6OP51UrsMeBuOD0X-dfFVtC7Nn8EeIrm4gBfJP3Di8bIEuNiTPu40-z_cOdt-SITMDKTMed8RZY72WS1JNVS64LkQpuKWa6ZTqmJkcAnZjQYHrXSsDudeZSVip_WEps35Lu4O26qa29xAuWa4Ysx7IeCgkHFdUaJcZrySpdoqZCCXjjMhyoC2H7Bnf5ES4HEZNxlBg1GQRoefTM6c9ace5tV_BRE81gXA7XGjaYzmsX1nQ3KjcpcbyjGlFFS1c4sGiMqn2MMlG6OkoJtIvULC6qNo265X0Z9pChPTpEbrbi830qrRI08KjpAjxDYHa-JbNO3V1EkjA_TGa0Zj5Rl-MciWH7Wd1Tmfv_1v1J2h7-Xou998t3j9AVyhIZnBkfIi2unZtH6HL5Y-uWrWPw7L7BcOUKCw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Laser+versus+Anti-VEGF%3A+A+Paradigm+Shift+for+Treatment-Warranted+Retinopathy+of+Prematurity&rft.jtitle=Ophthalmology+and+therapy&rft.au=Hartnett%2C+M+Elizabeth&rft.au=Stahl%2C+Andreas&rft.date=2023-10-01&rft.issn=2193-8245&rft.volume=12&rft.issue=5&rft.spage=2241&rft_id=info:doi/10.1007%2Fs40123-023-00744-7&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-8245&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-8245&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-8245&client=summon |